← Oncology Approval Tracker

FDA DECISION ·

Opdivo + AVD

nivolumab with doxorubicin, vinblastine and dacarbazine · Bristol Myers Squibb

FDA approvalNew or expanded indicationClassical Hodgkin lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults and adolescents age 12 or older with untreated stage III or IV classical Hodgkin lymphoma.

SUPPORTING DATA

Evidence behind the decision

Study
SWOG 1826 randomized 994 patients age 12 or older to nivolumab plus AVD or brentuximab vedotin plus AVD.
Key result
The progression-free survival hazard ratio was 0.42 (95% CI, 0.27–0.67) at 13.7 months median follow-up. The median was unreached in both groups.
Safety to report
In the nivolumab arm, 39% had serious adverse reactions and 9% had immune-mediated reactions.
Evidence limits
This trial supports the front-line combination. The same FDA notice covers separate traditional approvals for later-line monotherapy.

LAMPGEN ANALYSIS

Why it matters

This adds checkpoint blockade to front-line chemotherapy for advanced classical Hodgkin lymphoma, with randomized evidence that included adolescents.

What research teams should watch

Coordinate pediatric and adult workflows for immune toxicity, infection surveillance and growth factor prophylaxis. Keep first-line treatment separate from the simultaneous later-line conversions.

PRIMARY RECORDS

Sources